British Biotech plc -"British Biotech"- Board Change.Business Editors OXFORD, U.K.--(BUSINESS WIRE)--Aug. 7, 2001 British Biotech British Biotech was a British based biotech company. British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards, [1] (LSE LSE - Language Sensitive Editor : BBG BBG Brooklyn Botanic Garden BBG Broadcasting Board of Governors BBG Bloomberg (financial company) BBG Bundesbeamtengesetz (German Law) BBG Bergbau-Berufsgenossenschaft (Germany) , Nasdaq: BBIOY) announces that Dr. Giles Campion campion: see pink. campion Any of the ornamental rock-garden or border plants that make up the genus Silene, of the pink family, consisting of about 500 species of herbaceous plants found throughout the world. , Director of Research and Development and Chief Medical Officer, will step down from the Board and leave the Company at the end of September 2001. Research and Development functions will report directly to Dr Elliot Goldstein, the Chief Executive Officer. Chris Hampson, Chairman of British Biotech, said: "Giles has made a significant contribution to British Biotech. In the light of the changes to the business announced today, the Board has agreed to Giles' wish to pursue his career elsewhere. I would like to place on record my appreciation of his contribution and wish Giles every success in the future." This news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion